181 related articles for article (PubMed ID: 19519175)
1. Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor.
Langenheim JF; Chen WY
J Recept Signal Transduct Res; 2009; 29(2):107-12. PubMed ID: 19519175
[TBL] [Abstract][Full Text] [Related]
2. Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complex.
Xu J; Zhang Y; Berry PA; Jiang J; Lobie PE; Langenheim JF; Chen WY; Frank SJ
Mol Endocrinol; 2011 Apr; 25(4):597-610. PubMed ID: 21310852
[TBL] [Abstract][Full Text] [Related]
3. Prolactin antagonist-endostatin fusion protein as a targeted dual-functional therapeutic agent for breast cancer.
Beck MT; Chen NY; Franek KJ; Chen WY
Cancer Res; 2003 Jul; 63(13):3598-604. PubMed ID: 12839947
[TBL] [Abstract][Full Text] [Related]
4. The role of prolactin receptor in GH signaling in breast cancer cells.
Xu J; Sun D; Jiang J; Deng L; Zhang Y; Yu H; Bahl D; Langenheim JF; Chen WY; Fuchs SY; Frank SJ
Mol Endocrinol; 2013 Feb; 27(2):266-79. PubMed ID: 23192981
[TBL] [Abstract][Full Text] [Related]
5. Src transduces signaling via growth hormone (GH)-activated GH receptor (GHR) tyrosine-phosphorylating GHR and STAT5 in human leukemia cells.
Manabe N; Kubota Y; Kitanaka A; Ohnishi H; Taminato T; Tanaka T
Leuk Res; 2006 Nov; 30(11):1391-8. PubMed ID: 16650892
[TBL] [Abstract][Full Text] [Related]
6. A novel design of targeted endocrine and cytokine therapy for breast cancer.
Zhang G; Li W; Holle L; Chen N; Chen WY
Clin Cancer Res; 2002 Apr; 8(4):1196-205. PubMed ID: 11948133
[TBL] [Abstract][Full Text] [Related]
7. Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.
Langenheim JF; Tan D; Walker AM; Chen WY
Mol Endocrinol; 2006 Mar; 20(3):661-74. PubMed ID: 16269515
[TBL] [Abstract][Full Text] [Related]
8. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
9. GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers.
Liu Y; Zhang Y; Jiang J; Lobie PE; Paulmurugan R; Langenheim JF; Chen WY; Zinn KR; Frank SJ
Mol Endocrinol; 2016 May; 30(5):504-17. PubMed ID: 27003442
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of oncogene STAT3 phosphorylation by a prolactin antagonist, hPRL-G129R, in T-47D human breast cancer cells.
Cataldo L; Chen NY; Yuan Q; Li W; Ramamoorthy P; Wagner TE; Sticca RP; Chen WY
Int J Oncol; 2000 Dec; 17(6):1179-85. PubMed ID: 11078803
[TBL] [Abstract][Full Text] [Related]
11. Growth hormone (GH) receptor (GHR)-specific inhibition of GH-Induced signaling by soluble IGF-1 receptor (sol IGF-1R).
Zhang Y; Gc S; Patel SB; Liu Y; Paterson AJ; Kappes JC; Jiang J; Frank SJ
Mol Cell Endocrinol; 2019 Jul; 492():110445. PubMed ID: 31100495
[TBL] [Abstract][Full Text] [Related]
12. Spatio-temporal kinetics of growth hormone receptor signaling in single cells using FRET microscopy.
Biener-Ramanujan E; Ramanujan VK; Herman B; Gertler A
Growth Horm IGF Res; 2006 Aug; 16(4):247-57. PubMed ID: 16950496
[TBL] [Abstract][Full Text] [Related]
13. New mechanisms for PRLr action in breast cancer.
Clevenger CV; Gadd SL; Zheng J
Trends Endocrinol Metab; 2009 Jul; 20(5):223-9. PubMed ID: 19535262
[TBL] [Abstract][Full Text] [Related]
14. Subdomain 2, Not the Transmembrane Domain, Determines the Dimerization Partner of Growth Hormone Receptor and Prolactin Receptor.
Liu Y; Jiang J; Lepik B; Zhang Y; Zinn KR; Frank SJ
Endocrinology; 2017 Oct; 158(10):3235-3248. PubMed ID: 28977606
[TBL] [Abstract][Full Text] [Related]
15. Ligand-independent growth hormone receptor dimerization occurs in the endoplasmic reticulum and is required for ubiquitin system-dependent endocytosis.
Gent J; van Kerkhof P; Roza M; Bu G; Strous GJ
Proc Natl Acad Sci U S A; 2002 Jul; 99(15):9858-63. PubMed ID: 12105275
[TBL] [Abstract][Full Text] [Related]
16. The human growth hormone antagonist B2036 does not interact with the prolactin receptor.
Goffin V; Bernichtein S; Carrière O; Bennett WF; Kopchick JJ; Kelly PA
Endocrinology; 1999 Aug; 140(8):3853-6. PubMed ID: 10433247
[TBL] [Abstract][Full Text] [Related]
17. Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein tyrosine phosphatase-1B.
Choi JH; Kim HS; Kim SH; Yang YR; Bae YS; Chang JS; Kwon HM; Ryu SH; Suh PG
Nat Cell Biol; 2006 Dec; 8(12):1389-97. PubMed ID: 17128263
[TBL] [Abstract][Full Text] [Related]
18. Transduction pathways of GH in ovine mammary acini involving regulated and functional growth hormone receptors.
Chun EY; Belair L; Jolivet G; Djiane J; Jammes H
Growth Factors; 2005 Mar; 23(1):55-66. PubMed ID: 16019427
[TBL] [Abstract][Full Text] [Related]
19. A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling.
García-Martínez JM; Calcabrini A; González L; Martín-Forero E; Agulló-Ortuño MT; Simon V; Watkin H; Anderson SM; Roche S; Martín-Pérez J
Cell Signal; 2010 Mar; 22(3):415-26. PubMed ID: 19892015
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D3 cannot revert desensitization of growth hormone (GH)-induced STAT5-signaling in GH-overexpressing mice non-calcemic tissues.
Sotelo AI; Miquet JG; González L; Bartke A; Turyn D
Growth Horm IGF Res; 2008 Apr; 18(2):148-56. PubMed ID: 17881271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
